N-desalkylquetiapine activates ERK1/2 to induce GDNF release in C6 glioma cells: A putative cellular mechanism for quetiapine as antidepressant

Neuropharmacology

Volumn 62, Issue 1, 2012, Pages 209-216

  Di Benedetto, Barbara ^a   Kühn, Ralf ^c,d   Nothdurfter, Caroline ^a,b   Rein, Theo ^a   Wurst, Wolfgang ^c,d,e   Rupprecht, Rainer ^a,b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Antidepressant; C6 cells; ERK MAP kinase; GDNF; Norquetiapine; Quetiapine

Indexed keywords

ANTIDEPRESSANT AGENT; DRUG METABOLITE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NORQUETIAPINE; QUETIAPINE; REBOXETINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOMA CELL; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; RAT; RNA INTERFERENCE;

ANIMALS; ANTIDEPRESSIVE AGENTS; CELL LINE, TUMOR; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLIOMA; LACTATE DEHYDROGENASES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROPYLAMINES; PYRIDINES; RATS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 80054115722     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.07.001     Document Type: Conference Paper

References (28)

1. D.B. Allison, J.L. Mentore, M. Heo, L.P. Chandler, J.C. Cappelleri, M.C. Infante, and P.J. Weiden Antipsychotic-induced weight gain: a comprehensive research synthesis Am. J. Psychiatry 156 1999 1686 1696 (Pubitemid 29517559)
2. C. Andrade, and N.S.K. Rao How antidepressant drugs act: a primer on neuroplasticity as the eventual mediator of antidepressant efficacy Indian J. Psychiatry 52 2010 378 386
3. O. Bai, Z. Wei, W. Lu, R. Bowen, D. Keegan, and X.M. Li Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal J. Neurosci. Res. 69 2002 278 283 (Pubitemid 34734158)
4. M. Banasr, and R.S. Duman Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors Biol. Psychiatry 64 2008 863 870
5. B. Bortnick, N. El-Khalili, M. Banov, D. Adson, C. Datto, S. Raines, W. Earley, and H. Eriksson Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study J. Affect Disord 2010
6. S. Cohrs, A. Rodenbeck, Z. Guan, K. Pohlmann, W. Jordan, A. Meier, and E. Ruther Sleep-promoting properties of quetiapine in healthy subjects Psychopharmacology (Berl) 174 2004 421 429 (Pubitemid 39044301)
7. S. Cohrs, C. Roher, W. Jordan, A. Meier, G. Huether, W. Wuttke, E. Ruther, and A. Rodenbeck The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects Psychopharmacology (Berl) 185 2006 11 18 (Pubitemid 43289608)
8. D. Cussac, D. Duqueyroix, A. Newman-Tancredi, and M.J. Millan Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors Psychopharmacology (Berl) 162 2002 168 177 (Pubitemid 34743956)
9. A.J. Cutler, S.A. Montgomery, D. Feifel, A. Lazarus, M. Astrom, and M. Brecher Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study J. Clin. Psychiatry 70 2009 526 539
10. V. Duric, M. Banasr, P. Licznerski, H.D. Schmidt, C.A. Stockmeier, A.A. Simen, S.S. Newton, and R.S. Duman A negative regulator of MAP kinase causes depressive behavior Nat. Med. 16 2010 1328 1332
11. N. El-Khalili, M. Joyce, S. Atkinson, R.J. Buynak, C. Datto, P. Lindgren, and H. Eriksson Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study Int. J. Neuropsychopharmacol. 13 2010 917 932
12. P. Gajwani, D.J. Muzina, D.E. Kemp, K. Gao, and J.R. Calabrese Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies Neuropsychiatr Dis. Treat. 3 2007 847 853
13. K. Hisaoka, M. Takebayashi, M. Tsuchioka, N. Maeda, Y. Nakata, and S. Yamawaki Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine-independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells J. Pharmacol. Exp. Ther. 321 2007 148 157 (Pubitemid 46456986)
14. N.H. Jensen, R.M. Rodriguiz, M.G. Caron, W.C. Wetsel, R.B. Rothman, and B.L. Roth N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity Neuropsychopharmacology 33 2008 2303 2312
15. J.M. Kyriakis, and J. Avruch Sounding the alarm: protein kinase cascades activated by stress and inflammation J. Biol. Chem. 271 1996 24313 24316 (Pubitemid 26333156)
16. L.F. Lin, D.H. Doherty, J.D. Lile, S. Bektesh, and F. Collins GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 260 1993 1130 1132 (Pubitemid 23186789)
17. M.C. Mauri, L.S. Volonteri, A. Colasanti, A. Fiorentini, I.F. De Gaspari, and S.R. Bareggi Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response Clin. Pharmacokinet. 46 2007 359 388 (Pubitemid 46686464)
18. E.J. Nestler, M. Barrot, R.J. DiLeone, A.J. Eisch, S.J. Gold, and L.M. Monteggia Neurobiology of depression Neuron 34 2002 13 25 (Pubitemid 34270695)
19. M. Orsetti, P.L. Canonico, A. Dellarole, L. Colella, F. Di Brisco, and P. Ghi Quetiapine prevents anhedonia induced by acute or chronic stress Neuropsychopharmacology 32 2007 1783 1790 (Pubitemid 47076374)
20. G. Pages, P. Lenormand, G. L'Allemain, J.C. Chambard, S. Meloche, and J. Pouyssegur Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation Proc. Natl. Acad. Sci. U S A 90 1993 8319 8323 (Pubitemid 23277659)
21. X. Qi, W. Lin, J. Li, H. Li, W. Wang, D. Wang, and M. Sun Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress Neurobiol. Dis. 31 2008 278 285
22. G. Rajkowska, and J.J. Miguel-Hidalgo Gliogenesis and glial pathology in depression CNS Neurol. Disord. Drug Targets 6 2007 219 233 (Pubitemid 46916253)
23. V. Rubovitch, M. Gafni, and Y. Sarne The involvement of VEGF receptors and MAPK in the cannabinoid potentiation of Ca2+ flux into N18TG2 neuroblastoma cells Brain Res. Mol. Brain Res. 120 2004 138 144 (Pubitemid 38115810)
24. Z. Shao, L.E. Dyck, H. Wang, and X.M. Li Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells J. Psychiatry Neurosci. 31 2006 32 37
25. T. Suppes, C. Datto, M. Minkwitz, A. Nordenhem, C. Walker, and D. Darko Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression J. Affect Disord. 121 2010 106 115
26. J.D. Weber, D.M. Raben, P.J. Phillips, and J.J. Baldassare Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase Biochem. J. 326 Pt 1 1997 61 68 (Pubitemid 27386918)
27. R. Weisler, M. Joyce, L. McGill, A. Lazarus, J. Szamosi, and H. Eriksson Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study CNS Spectr. 14 2009 299 313
28. P. Yuan, R. Zhou, Y. Wang, X. Li, J. Li, G. Chen, X. Guitart, and H.K. Manji Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia J. Affect Disord. 124 2010 164 169